Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Queensland Health
Accenture
Farmers Insurance
Harvard Business School
Cipla

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,012,480

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,012,480
Title:Detection of proteins from circulating neoplastic cells
Abstract: The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated with an anti-EGFR agent, for example cetuximab, panitumumab, erlotinib or gefitinib.
Inventor(s): Lorence; Robert M. (Bethesda, MD)
Assignee: Wellstat Biologics Corporation (Gaithersburg, MD)
Application Number:12/297,420
Patent Claims:1. A method of assaying a protein from cancer cells in a blood sample comprising enriching the cancer cells from the blood sample followed by lysing the enriched cells and performing on the lysed cancer cells an immunoassay capable of detecting the protein from the cancer cells; wherein the immunoassay uses electrochemiluminescence for detection the immunoassay has a sensitivity defined by being capable of quantifiably detecting the protein from thirty cancer cells per milliliter of blood or by being capable of detecting sixty-four picograms of the protein; and the protein is selected from the group consisting of epidermal growth factor receptor, excision repair cross-complementation group 1, ribonucleotide reductase subunit M1, thymidylate synthase, and beta-tubulin; and the immunoassay generates a signal proportional to the number of molecules of the protein present in the cancer cells in the blood sample.

2. A method of detecting the expression of a protein from cancer cells in a blood sample comprising isolating the cancer cells from the blood sample followed by making an extract from the isolated cancer cells followed by performing on the extract an immunoassay capable of detecting the protein, in which a positive immunoassay result indicates the presence of the protein in the cancer cells; wherein the immunoassay uses electrochemiluminescence for detection the protein is epidermal growth factor receptor; and the immunoassay has a sensitivity defined by being capable of detecting the protein from thirty cancer cells per milliliter of blood or by being capable of detecting sixty-four picograms of the protein.

3. The method of claim 1, wherein the immunoassay is capable of detecting the protein from ten cancer cells per milliliter of blood.

4. The method of claim 3, wherein the immunoassay is capable of detecting the protein from three cancer cells per milliliter of blood.

5. The method of claim 1, wherein the immunoassay is capable of detecting four picograms of the protein.

6. A method of treating a cancer patient likely to benefit from treatment with an anti-EGFR agent, comprising administering the agent to the patient whose blood sample tested positive for epidermal growth factor receptor in the method of claim 1.

7. The method of claim 6 wherein the agent is selected from the group consisting of cetuximab, panitumumab, erlotinib, and gefitinib.

8. The method of claim 2, wherein the immunoassay is capable of detecting the protein from ten cancer cells per milliliter of blood.

9. The method of claim 8, wherein the immunoassay is capable of detecting the protein from three cancer cells per milliliter of blood.

10. The method of claim 2, wherein the immunoassay is capable of detecting four picograms of the protein.

11. A method of treating a cancer patient likely to benefit from treatment with an anti-EGFR agent, comprising administering the agent to the patient whose blood sample tested positive in the method of claim 2.

12. The method of claim 11 wherein the agent is selected from the group consisting of cetuximab, panitumumab, erlotinib, and gefitinib.

Summary for Patent: ➤ Sign Up

PCT Information
PCT FiledApril 18, 2007PCT Application Number:PCT/US2007/066857
PCT Publication Date:October 25, 2007PCT Publication Number:WO2007/121465

Details for Patent 8,012,480

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up Wellstat Biologics Corporation (Gaithersburg, MD) 2036-04-30 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27 ➤ Sign Up Wellstat Biologics Corporation (Gaithersburg, MD) 2036-04-30 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27 ➤ Sign Up Wellstat Biologics Corporation (Gaithersburg, MD) 2036-04-30 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27 ➤ Sign Up Wellstat Biologics Corporation (Gaithersburg, MD) 2036-04-30 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 8,012,480

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2007121465 Jun 19, 2008
World Intellectual Property Organization (WIPO) 2007121465 Oct 25, 2007
World Intellectual Property Organization (WIPO) 2007121465 Sep 12, 2008
United States of America 2009098138 Apr 16, 2009
Mexico 2008013332 Nov 10, 2008
Japan 2009534667 Sep 24, 2009
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
Fuji
Cantor Fitzgerald
Colorcon
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.